

### KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Centre& Hospital) Coimbatore-641014, Tamil Nadu



## DEPARTMENT OF PHARMACOLOGY

# NEW DRUG UPDATE

Series No: 60, JUNE, 2024

| S.NO | DRUG &<br>APPROVAL DATE                                | MECHANISM   | INDICATION   | DOSAGE<br>FORMS          |
|------|--|---|--|--------------------------|
| 1.   | Imetelstat<br>June 6, 2024                             | Oligonucleotide<br>telomerase inhibitor   | Myelodysplastic<br>syndromes (MDS) with<br>transfusion dependent<br>anemia | Intravenous<br>infusion  |
| 2.   | Elafibranor<br>June 10,2024                            | Peroxisome-activat<br>ed receptor (PPAR)<br>alpha/delta (α,δ)<br>agonist          | Primary Biliary<br>Cholangitis   | Tablet                   |
| 3    | Immune globulin G<br>(IgG) 10% liquid<br>June 13, 2024 | Immunomodulatory<br>effects   | Primary humoral<br>immunodeficiency  | Intravenous<br>injection |
| 4    | Vigabatrin<br>June 17, 2024                            | Inhibiting the<br>enzyme GABA<br>transaminase -<br>increasing<br>gamma-aminobutyr | Infantile spasms   | Oral solution            |



### KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Centre& Hospital) Coimbatore-641014, Tamil Nadu



|    |   | ic acid (GABA)<br>levels in the brain  |  |  |
|----|---|--|--|--|
| 5  | Pneumococcal 21<br>valent conjugate -<br>Single dose vaccine<br>June 17, 2024 | Opsonophagocytic<br>activity (OPA)<br>against 22 <i>S.</i><br><i>pneumoniae</i><br>serotypes | Prevention of invasive<br>disease and pneumonia in<br>adults 18 years of age and<br>older. | Intramuscular<br>Injection                     |
| 6  | Sofpironium<br>June 18, 2024  | Antimuscarinic<br>drug   | Primary axillary<br>Hyperhidrosis  | Topical gel                                    |
| 7. | Crovalimab-akkz<br>June 20, 2024  | Complement C5<br>inhibitor   | Paroxysmal nocturnal<br>Hemoglobinuria   | Intravenous<br>or<br>Subcutaneous<br>Injection |
| 8  | Thiotepa<br>June 25, 2024   | Alkylating agent   | Breast Cancer, Ovarian<br>Cancer   | Intravenous injection                          |
| 9  | Ensifentrine<br>June 26, 2024   | Dual inhibitor of<br>Phosphodiesterase<br>3 (PDE3) and<br>Phosphodiesterase<br>4 (PDE4)      | Chronic obstructive<br>pulmonary disease<br>(COPD) in adult patients.                      | Solution for inhalation                        |
| 10 | Aflibercept-mrbb<br>June 28, 2024   | Vascular<br>endothelial growth   | Macular Degeneration,<br>Macular Edema Following<br>Retinal Vein Occlusion,                | Ophthalmic<br>Injection                        |



### KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH (A unit of Kovai Medical Centre& Hospital) Coimbatore-641014, Tamil Nadu



|                  | factor (VEGF)      | Diabetic Macular Edema,                              |   |
|------------------|--------------------|--|---|
|                  | inhibitor          | Diabetic Retinopathy                                 |   |
| Ustekinumab-ttwe | Human              | Plaque Psoriasis, Psoriatic                          | Intravenous   |
| June 28, 2024    | interleukin-12 and | Arthritis, Crohn's Disease,                          | infusion or   |
|                  | -23 antagonist     | Ulcerative Colitis                                   | Subcutaneous  |
|                  |                    |  | Injection   |
|                  |                    | Ustekinumab-ttweHumanJune 28, 2024interleukin-12 and | inhibitorDiabetic RetinopathyUstekinumab-ttweHumanJune 28, 2024interleukin-12 andPlaque Psoriasis, PsoriaticArthritis, Crohn's Disease, |

#### Contact Details:

**Email your suggestions to :** <u>hodpharmacology@kmchihsr.edu.in</u>

Website : <u>http://www.kmchihsr.edu.in</u>